Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Antidepressant Safety Plan Includes "Black Box," Unit-Of-Use Packaging

This article was originally published in The Pink Sheet Daily

Executive Summary

Unit-of-use packaging will ensure distribution of patient MedGuides, FDA says. Agency asks all antidepressant manufacturers to add "black box" warning, as recommended by advisory committee in September.

You may also be interested in...



CDER’s Neurology Division Prepares For New Leadership With Director Katz’s Retirement

Russell Katz will retire following a 30-year career at FDA; his departure comes as the agency is embarking on new efforts to encourage drug development for Alzheimer’s disease and amyotrophic lateral sclerosis.

FDA Psychiatry Division To Be Headed By Laughren Under Restructuring Plan

Neuropharmacological reviewer Laughren will head FDA's psychiatric drug reviews after the division is spun off under the Office of New Drugs reorganization. Laughren's appointment is one of few top-level promotions under the restructuring effort.

FDA Psychiatry Division To Be Headed By Laughren Under Restructuring Plan

Neuropharmacological reviewer Laughren will head FDA's psychiatric drug reviews after the division is spun off under the Office of New Drugs reorganization. Laughren's appointment is one of few top-level promotions under the restructuring effort.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel